KR101556467B1 - Composition for preventing or improving of circulatory disturbance disease comprising Camellia japonica extract - Google Patents

Abstract

The present invention relates to a composition for preventing or ameliorating a disorder of blood circulation comprising a camellia extract as an active ingredient. The camellia extract contained as an active ingredient in the composition of the present invention shows a blood vessel relaxation effect improved by about 9 to 50 times or more as compared with the conventional ginkgo leaf extract, which is a natural vascular relaxant. Therefore, a cosmetic for preventing or improving a blood circulation disorder disease And pharmaceutical compositions.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing or ameliorating a circulatory disturbance disorder comprising camellia extract as an active ingredient, and a composition for preventing or ameliorating a circulatory disturbance disease comprising Camellia japonica extract.

The present invention relates to a composition for preventing or ameliorating a disorder of blood circulation comprising a camellia extract as an active ingredient.

Blood circulation is the circulation of blood along the blood vessels around the heart. It supplies oxygen to the tissues of the body, releases carbon dioxide, supplies nutrients, releases metabolites, It refers to the process of transporting hormones to perform functions such as regulation of specific organs, regulating pathogens, regulating body temperature, controlling osmotic pressure, and controlling water content. However, when blood circulation obstacle occurs, blood vessels extending in all corners of the body lose their elasticity and cholesterol accumulates on the inner wall of the body, narrowing the lumen of the blood vessels and causing narrowed limbs, pulled backs, shoulder stiffness, weakening of memory, lethargy, dizziness, chronic fatigue, Diseases, etc., and it is difficult to maintain normal life.

According to the statistics of the World Health Organization (WHO), the mortality rate due to cardiovascular diseases among the above-mentioned blood circulation disorders is increasing every year and it is reported that the growth rate of Asia such as Japan and Korea is high. It is widely known that such cardiovascular diseases involve intake of processed foods with low fat content and dietary fiber content, genetic factors, smoking, drinking, hypertension, arteriosclerosis, diabetes, obesity, lack of exercise, and excessive stress. These lesions are characterized by physical or chemical scars that cause damage to the surface of the monolayer of blood vessels, and thrombus adhesion receptors capable of inducing thrombus formation in the blood vessel wall are expressed. Monocytes, T- T-lympocytes and platelets adhere to the blood vessels through the vascular endothelial cells. At this time, lipid proteins in the blood also enter the blood vessels. The monoliths that enter the blood vessel walls digest lipid proteins and transform them into macrophages, and macrophages accumulate cholesterol to form cells. The foam cells repeatedly irritate inflammation and cell growth, destroying or enlarging the blood vessel walls, and causing platelets in the blood to adhere to form blood clots. This progression eventually leads to myocardial infarction death due to temporary blockage of blood supply to the heart due to stenosis of the arteries due to arteriosclerosis and complete closure of blood vessels due to thrombosis.

In order to prevent or treat diseases caused by the above-mentioned blood circulation disorder, such as limbs, back pounding, shoulder stiffness, loss of memory, lethargy, dizziness, chronic fatigue and hypertension and arteriosclerosis, medroxyprogesterone acetate, Vascular relaxants including chemicals such as progesterone and estrogen have been used. However, when the above-mentioned chemical substances are continuously used, the incidence of cancer is increased and there is a problem of stability. Therefore, recently, there is a need for a medicinal herb that is safe from the side effects of natural products and has an effect of improving diseases caused by blood circulation disorders Research is under way.

In this regard, Korean Patent Registration No. 1247633 discloses a herbal medicine extract which is effective for promoting blood vessel relaxation, lowering blood pressure, and reducing a cerebral infarction area, and which is composed of Angelica keiskei, a medicinal herb, an ophiolate, a herbal supplement, a jojoba, a safflower, Korean Patent No. 0948332 discloses a composition for prevention and treatment of cardiovascular diseases including a large shrimp swine extract, and Korean Patent No. 0833705 Discloses a blood circulating agent or vasodilator which contains extracts of Orira ( Anoraeusus leiocarpus ), Gboigboi (Cnestis sp. ) Or Osusu (Drypetus molunduana ) with excellent vasorelaxation effect have. However, by using the extract of Camellia sinensis as in the present invention, it is possible to prevent diseases such as limb swallowing, triceps, shoulder stiffness, memory loss, lethargy, dizziness, chronic fatigue and hypertension and arteriosclerosis caused by blood circulation disorder Or improving vascular relaxation efficacy.

Accordingly, the present inventors have made efforts to develop a composition for preventing or ameliorating a plant-derived circulation disorder disease, which is harmless to human body and has excellent safety and effect by using natural products. As a result, it has been found that a composition comprising an extract of Camelliaceae as an effective ingredient, It was confirmed that the relaxation effect was remarkably excellent, and the present invention was completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or ameliorating a blood circulation disorder disease comprising an extract of Camelliaceae as an active ingredient.

It is another object of the present invention to provide a food composition for preventing or ameliorating a disorder of blood circulation comprising a camellia extract as an active ingredient.

TECHNICAL FIELD The present invention relates to a pharmaceutical composition for preventing or ameliorating a blood circulation disorder disease comprising a camellia extract as an active ingredient.

In the present invention, the camellia japonica L is a broad-leaved evergreen tree belonging to the genus Chamaecypis, widely distributed in Jeonbuk, Changnam, Haenam, Wando, Kangjin, Yeosu and Gwangyang. Camellia seeds have long been used as head oil or cooking oil, and flowers have been known to be effective for burns, and stem has been used as a raw material for high quality charcoal. In addition, it is known that it is effective for liver disease, skin diseases (whitening, spots, acne, wrinkle improvement, etc.), antioxidant, antibacterial and immunity enhancement. However, the efficacy of camellia for blood relaxation is not yet known.

In the present invention, the camellia extract may be at least one selected from the group consisting of camellia leaves, stem, flower, peel and fruit.

In the present invention, the Camellia sinensis extract can be extracted using water or an organic solvent, and the extracted liquid can be used in a liquid form or can be used by concentration and / or drying. The organic solvent may include, but is not limited to, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, preferably methanol, ethanol, butanol, hexane, dichloromethane, ethyl acetate or a mixed solvent thereof, Can be extracted at room temperature or warming under non-destructive or minimized conditions. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the extract may differ. Therefore, an appropriate organic solvent should be selected and used. The extraction method of the organic solvent is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction.

The purified water is a process for removing suspended solid particles from an extract or a fraction. The purified water may be filtered using a cotton, nylon, or the like, or an ultrafiltration method, a freezing filtration method, a centrifugation method, or the like. In addition, it may further comprise a separation process by various chromatographies (size, charge, hydrophobicity or affinity chromatographic).

The method of concentration and / or drying includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like. In some cases, a step of pulverizing the final dried extract may be added.

The pharmaceutical composition of the present invention has a use for preventing or ameliorating a disease caused by a blood circulation disorder. As an example, the camellia extract of the present invention exhibits about 9 to 50 times more vascular relaxation effect than the ginkgo leaf extract, which is used as a conventional natural vascular relaxant.

Accordingly, the pharmaceutical composition of the present invention can be applied to various blood circulation disorder diseases, diseases or abnormal conditions which can be prevented or treated by controlling blood circulation or vascular relaxation. The diseases caused by the blood circulation disorder include, for example, hypertension, diabetes mellitus, arteriosclerosis, ischemic heart disease, coronary artery disease, angina pectoris, shoulder stiffness, memory decline, lethargy, dizziness, chronic fatigue, stroke, myocardial infarction Cerebrovascular disease, and the like.

As used herein, the term "prophylactic " means inhibiting the occurrence of a disease or disorder in an individual who has never been diagnosed as having a disease or condition, but is likely to be susceptible to such disease or disease. As used herein, the term " treatment "or" improvement "means (a) inhibiting the development of a disease or disorder in an individual; (b) relieving the disease or disorder; As used herein, the term " individual " means a mammal, including a human, having a disease whose symptoms may be ameliorated by administration of the composition of the present invention, such as a monkey, cow, horse, pig, sheep, dog, cat, rat, Means a mammal.

In the present invention, the pharmaceutical composition may contain a pharmaceutically acceptable carrier other than the camellia extract. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include carbohydrate-based compounds such as lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc. ), Acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solution, alcohol, gum arabic, vegetable oil But are not limited to, vegetable oils, soybean oil, soybean oil, olive oil, coconut oil), polyethylene glycol, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above-mentioned components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably by local administration by application.

The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . On the other hand, the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg (body weight) per day. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day for one month or longer. However, the dose is not intended to limit the scope of the present invention.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The active ingredient of the camellia extract is 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.0001 to 5% by weight, based on the total composition. When the weight of the camellia extract is less than 0.00001% by weight, the blood vessel relaxation effect is weak. When the weight of the camellia extract is more than 15% by weight, the effect of increasing the content is very weak.

The present invention also relates to a food composition for preventing or ameliorating a disorder of blood circulation comprising an extract of Camelliaceae as an active ingredient.

In the present invention, the food composition of the present invention may contain components other than the above-mentioned Camellia sinensis extract, which are conventionally added in food production. For example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. The above-mentioned carbohydrates are polysaccharides such as disaccharides such as monosaccharides of glucose and fructose sugars, maltose, sucrose and oligosaccharides, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. The flavoring agent may be a natural flavoring agent (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavorings (saccharin, aspartame, etc.).

There is no particular limitation on the kind of the food. Examples of the food to which the camellia extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

When the food of the present invention is a beverage, it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame, and the like .

The food may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the health food of the present invention may contain natural fruit juice, pulp for the production of beverages and vegetable drinks. These components may be used independently or in combination.

The active ingredient of the camellia extract is 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.0001 to 5% by weight, based on the total composition. When the weight of the camellia extract is less than 0.00001% by weight, the blood vessel relaxation effect is weak. When the weight of the camellia extract is more than 15% by weight, the effect of increasing the content is very weak.

Since the camellia extract of the present invention exhibits a blood vessel relaxation effect improved by about 9 to 50 times as compared with the conventional ginkgo leaf extract, which is a natural vascular relaxant, it can be applied to cosmetic and pharmaceutical compositions for preventing or ameliorating a blood circulation disorder disease have.

FIG. 1 shows the vascular relaxation effect according to the concentrations of camellia leaves, stems, flowers, peel or fruit extract of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention, and it is to be understood by those skilled in the art that the present invention is not limited thereto It will be obvious.

Example 1: Preparation of Extracts of Camellia sinensis

1-1. Collection of samples

Camellia leaves, stems, flowers, peel and fruit to be used for the experiment were collected in 2013 from camellia growing in Jeonnam Forest Resources Research Institute.

1-2. Camellia extract preparation

The samples collected in Example 1-1 were lyophilized and pulverized, and then 500 g of each of them was added to 2 L of methanol. Ultrasonic waves were then extracted at 45 캜 for 15 minutes and allowed to stand for 2 hours. This extraction method is repeated 10 times a day and 30 times for 3 days. Then, the extract solution was filtered with a filter paper of Whatman, Advantes, No. 2, and then concentrated under reduced pressure and lyophilized to prepare camellia leaves, stems, flowers, peel or fruit extracts.

Example 2: Measurement of vascular relaxation effect of Camellia sinensis extract

The relaxation effect of the coronary artery of the pig heart was measured to confirm the vascular relaxation effect of the camellia leaves, stem, flower, peel or fruit extract extracted in Example 1 above. First, after purchasing a pig heart immediately after slaughter in a slaughterhouse and extracted coronary artery 18 mM NaCl, 4.7 mM KCl, 1.1 mM MgSO 4, 1.2 mM KH 2 PO 4, 1.5 mM CaCl 2, 25 mM NaHCO 3, 10 mM glucose in a Krebs solution (pH 7.4) and the connective tissue and fat were removed, and the sections were cut to a length of about 3 mm. The coronary artery was then fixed in a Krebs solution at 37 ° C saturated with 95% O ₂ and 5% CO ₂ gas and then diluted with a thromboxane derivative U46619 (1-60 nM) to 80% of the maximum vessel contraction for 10 minutes Lt; / RTI > Then, the stability of vascular endothelial cells was measured by relaxation reaction with 300 nM of Bradykinin, and then washed three times with Krebs solution. Then, the corneal artery was shrunk to U45519, and the camellia leaves, stem, flower, peel or fruit extract prepared in Example 1 were diluted with 0.1, 0.3, 1, 3, 10, 30 and 100 μg / ml and the isometric tension was measured using a physiological recorder (Grass physiograph, HugoSachs, Germany) equipped with a force-displacement transducer (HugoSachs, Germany) . As a control group, Ginkgo biloba extract used as a conventional vascular protective agent was used. The ED ₅₀ value was calculated by multiplying the concentration (㎍ / ml) of the sample with 50% vessel relaxation by the shrinkage of the blood vessels . The results are shown in Table 1 and Fig.

part ED ₅₀ ([mu] g / ml) Control group (Ginkgo biloba extract) 285 Camellia leaf 30 stem 20 Flower 21.3 pericarp 12.5 Fruit 5

As shown in FIG. 1, the camellia leaves, stems, flowers, or pea extracts began to relax significantly from the concentration of 1 to 10 μg / ml, and 50%, 80%, 72% , And 61% relaxation. Camellia fruit extract began to relax significantly from the concentration of 1 to 3 ㎍ / ml and relaxed about 93% at 10 ㎍ / ml and 105% at 30 ㎍ / ml.

On the other hand, as shown in Table 1, camellia leaves, stem, flower, peel, and fruit extracts exhibited blood relaxation effects of about 9 times, 15 times, 13 times, 23 times, and 50 times, respectively, , And the fruit extract showed the highest blood relaxation effect in comparison with control, camellia leaves, stem, flower or perilla extract.

Therefore, leaf, stem, flower, peel or fruit extract of Camellia sinensis showed high blood vessel relaxation effect, and especially fruit extract had the highest vascular relaxation efficacy.

Claims (6)

A pharmaceutical composition for preventing or ameliorating a blood circulation disorder disease comprising an extract of Camellia yezoensis as an active ingredient.
delete The method according to claim 1, wherein the disorder of blood circulation disorder is selected from the group consisting of hypertension, diabetes, arteriosclerosis, ischemic heart disease, coronary artery disease, angina pectoris, shoulder stiffness, memory loss, weakness, dizziness, chronic fatigue, stroke, myocardial infarction, Or a pharmaceutically acceptable salt thereof.
A food composition for preventing or improving a blood circulation disorder disease comprising an extract of Camellia yezoensis as an active ingredient.
delete 5. The method of claim 4, wherein the disorder of blood circulation is selected from the group consisting of hypertension, diabetes, arteriosclerosis, ischemic heart disease, coronary artery disease, angina pectoris, shoulder stiffness, memory loss, lethargy, dizziness, chronic fatigue, stroke, myocardial infarction, Or a disease.

Images